Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference on May 18, 2021 at 10:55 a.m. Eastern Time. The presentation will feature CFO Matt Abernethy and CMO Eiry Roberts. Interested parties can access the live webcast on the company's website, with a replay available afterward for one month. Neurocrine focuses on innovative treatments for neurological and psychiatric disorders, with a portfolio that includes FDA-approved therapies for tardive dyskinesia and Parkinson's disease.

News Market Reaction – NBIX

+0.77%

+0.77% Session move

In the trading session that priced this news, NBIX gained 0.77%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 2021. Matt Abernethy, Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-2021-rbc-global-healthcare-conference-301288859.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences present at the RBC Capital Markets Healthcare Conference?

Neurocrine Biosciences will present on May 18, 2021, at 10:55 a.m. Eastern Time.

Who will represent Neurocrine Biosciences at the conference?

CFO Matt Abernethy and CMO Eiry Roberts will represent Neurocrine Biosciences.

How can I access the Neurocrine Biosciences presentation?

The live presentation can be accessed via webcast on the Neurocrine website under the Investors section.

Is there a replay available for the Neurocrine presentation?

Yes, a replay will be available approximately one hour after the presentation and will be archived for about one month.

What is the focus of Neurocrine Biosciences?

Neurocrine Biosciences specializes in treatments for serious neurological, endocrine, and psychiatric disorders.